

- B
Cont*
79. A pharmaceutical composition comprising the TNF inhibitor encoded by the nucleic acid of Claim 77.
80. A recombinant DNA expression vector comprising a nucleic acid sequence of Claim 76.
81. A recombinant host cell comprising the expression vector of Claim 80.
82. A recombinant host cell of Claim 81 wherein said cell is a eukaryote or a prokaryote.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

Claims 25-75 were pending in this application, and have been cancelled without prejudice. New claims 76-82 have been added. The Applicants contend that no new matter has been added as a result of the above-described amendments. The subject matter of claims 76-77 is described at, for example, page 70 of the originally filed application. Similarly, the subject matter of claims 78-79 is described at, for example, page 38, lines 1-12. And, the subject matter of claims 80-82 is described at page 19, line 30 to page 26, line 37. With entry of this amendment, the currently pending claims are 76-82.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

By:



Kevin E. Noonan, Ph.D.
Reg. No. 35,303

Date: 08/12/99